Brenda Lormil

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Diffusion Weighted Imaging

Tyrosine Kinase

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A Boezio, Lucian DiPietro, Adam Frost, Fabrizio Giordanetto, Erika Paige Hamilton, Katherine Harris, Michael J Holliday, Tamieka L Hunter, Amanda Iskandar, Yongli Ji, Alexandre Larivée, Jonathan R LaRochelle, Andre Lescarbeau, Fabien Llambi, Brenda Lormil, Mary M Mader, Brenton G Mar, Iain Martin, Thomas H McLean, Klaus Michelsen, Yakov Pechersky, Erika G Puente, Ramin Samadani, Alison M Schram, Kelley Shortsleeves, Sweta Swaminathan, Shahein Tajmir, Gege Tan, Yong Tang, Roberto Valverde, Bryan Wehrenberg, Jeremy Wilbur, Bret R Williams, Hongtao Zeng, W Patrick Walters, Beni B Wolf, David E Shaw, Donald A Bergstrom, James Watters, Brian K Shoichet, Pascal D Fortin, D Randal Kipp
Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer discovery (2023)